title: Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.
abstract: OBJECTIVE
  Hurler syndrome is a debilitating genetic disease with a typical life span of 5 to 8 years. Early hematopoietic stem cell transplantation (HSCT) mitigates disease symptoms and improves survival. However, morbidity and mortality associated with HSCT can limit its success. We describe the initial experience with combined use of enzyme replacement therapy (ERT, laronidase) and HSCT in Hurler syndrome.
  
  
  METHODS
  Thirteen transplants were performed in 12 patients. ERT was given at a standard dose of 0.58 mg/kg per week. Transplant conditioning regimen and donor graft source were determined by institutional protocol.
  
  
  RESULTS
  The median age at initiation of ERT was 12 months (range, 8 to 18 months). The median duration of pre-HSCT ERT was 12 weeks (range, 4 to 28). All but 1 patient tested showed decrease in urinary GAG excretion during ERT. ERT infusion-related toxicity was limited to mild reactions. Development of antibodies to laronidase did not correlate with infusion reactions or responses in urinary GAG excretion. ERT was given for a median of 7 weeks (range, 3 to 20) after HSCT. After transplantation, eight patients demonstrated complete donor engraftment and four suffered graft failure. Two patients required ventilator support and three developed acute GVHD. Eleven of the 12 patients are surviving with a median follow-up of 3 months (range, 1 to 7 months).
  
  
  CONCLUSIONS
  In children with Hurler syndrome, ERT with HSCT is feasible and well tolerated. Development of antibodies against exogenous enzyme does not appear to correlate with infusion reactions or response to ERT. A prospective study is needed to determine the effect of concomitant ERT on transplant outcomes.
authors.affiliation: Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA.
authors.forename: Satkiran S
authors.initials: SS
authors.lastname: Grewal
authors.forename: Robert
authors.initials: R
authors.lastname: Wynn
authors.forename: Jose E
authors.initials: JE
authors.lastname: Abdenur
authors.forename: Barbara K
authors.initials: BK
authors.lastname: Burton
authors.forename: Maged
authors.initials: M
authors.lastname: Gharib
authors.forename: Claudia
authors.initials: C
authors.lastname: Haase
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Hayashi
authors.forename: Shalini
authors.initials: S
authors.lastname: Shenoy
authors.forename: David
authors.initials: D
authors.lastname: Sillence
authors.forename: George E
authors.initials: GE
authors.lastname: Tiller
authors.forename: Martha E
authors.initials: ME
authors.lastname: Dudek
authors.forename: Annet
authors.initials: A
authors.lastname: van Royen-Kerkhof
authors.forename: James E
authors.initials: JE
authors.lastname: Wraith
authors.forename: Paul
authors.initials: P
authors.lastname: Woodard
authors.forename: Guy A
authors.initials: GA
authors.lastname: Young
authors.forename: Nico
authors.initials: N
authors.lastname: Wulffraat
authors.forename: Chester B
authors.initials: CB
authors.lastname: Whitley
authors.forename: Charles
authors.initials: C
authors.lastname: Peters
mesh_terms: D000208:Acute Disease; D003131:Combined Modality Therapy; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007068:Iduronidase / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D008059:Mucopolysaccharidosis I / Q000188:drug therapy*; D011994:Recombinant Proteins; D012121:Respiration, Artificial; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D007068:Iduronidase